Posted by Michael Wonder on 16 Oct 2017
GSK announces first approval of Shingrix in Canada
13 October 2017 - The only shingles vaccine to achieve ≥90% efficacy in adults aged 50 and over.
GlaxoSmithKline today announced that Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older.
Shingrix is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses.
